Fourteen novel device or indication approvals were added to Medtech Insight's Approvals Tracker last week. Diabetes devices got the most attention, along with hemodialysis and a range of other clinical specialties.
The diabetes focus aligned with the American Diabetes Association annual meeting (June 22-26 in Orlando, Fla.). Tandem Diabetes Care Inc. entered the predictive automated insulin delivery space with US FDA PMA approval of its t:slim X Insulin Pump with Basal-IQ on June 21. The system Tandem's first "low glucose suspend" device, meaning it employs an algorithm (Basal-IQ) to predict glucose trends and automatically shuts off insulin delivery if low glucose is predicted, and restarts once glucose levels begin to rise
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?